Virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial

被引:6
|
作者
You, John J. [1 ,2 ]
Liu, Yudong [3 ]
Kirby, John [4 ]
Vora, Parag [5 ]
Moayyedi, Paul [1 ]
机构
[1] McMaster Univ, Dept Med, Hamilton, ON L8S 4K1, Canada
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4K1, Canada
[3] Univ Western Ontario, Fac Dent, London, ON N6A 5C1, Canada
[4] Connolly Hosp Blanchardstown, Dept Radiol, Dublin, Ireland
[5] McMaster Univ, Dept Radiol, Hamilton, ON L8S 4K1, Canada
来源
TRIALS | 2015年 / 16卷
关键词
Colonoscopy; Colorectal cancer; Computed tomography colonography; Fecal occult blood testing; pilot study; Prevention; Randomized controlled trial; Screening; Virtual colonoscopy; CT COLONOGRAPHY;
D O I
10.1186/s13063-015-0826-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: No head-to-head randomized controlled trials have demonstrated the superiority of one colorectal screening modality over another in reducing colorectal cancer mortality. We conducted a pilot randomized controlled trial of fecal occult blood testing (FOBT), optical colonoscopy (OC), and virtual colonoscopy (VC), to inform the planning of a larger evaluative trial. Methods: Eligible patients (aged 50 to 70) were recruited from five primary care practices in Hamilton, ON, Canada, between March 23, 2010 and August 11, 2010, and randomized 1:1:1 in a parallel design using an automated, centralized telephone service to either FOBT, OC, or VC. To reflect conventional practice, patients received no additional reminders to complete their allocated screening test beyond those received in usual practice. The primary outcome was completion of the assigned screening procedure. Results of the index test and any follow-up investigations were ascertained at 6 months. Participants, caregivers, and outcome assessors were not blinded to group assignment. The trial was stopped early due to lack of ongoing funding. Results: A total of 198 participants were enrolled, of whom 67 were allocated to FOBT, 66 to OC, and 65 to VC. The allocated screening procedure was completed by 43 (64 %) subjects allocated to FOBT (95 % confidence interval [CI], 52-75 %), 53 (80 %) subjects allocated to OC (95 % CI, 69-88 %), and 50 (77 %) subjects allocated to VC (95 % CI, 65-85 %); because the trial stopped early, we had insufficient statistical power to detect clinically relevant differences in completion rates. During 6 months follow-up, colorectal adenomas were detected in 0 (0 %) subjects allocated to FOBT, 12 (18 %) subjects allocated to OC, and 2 (3 %) subjects allocated to VC. One subject in the OC arm had histological evidence of high-grade dysplasia. No subjects were diagnosed with colorectal cancer. Conclusions: In this pilot randomized controlled trial of colorectal cancer screening in a primary care setting, 64-80 % of subjects completed their allocated screening test. These findings may be of value to investigators planning clinical trials to evaluate the effectiveness of colorectal cancer screening.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Fecal occult blood testing for colorectal cancer screening - Response
    Cotterill, M
    Gasparelli, R
    Kirby, E
    CANADIAN FAMILY PHYSICIAN, 2005, 51 : 1616 - 1617
  • [42] Fecal occult blood testing as a screening procedure for colorectal cancer
    Lowenfels, AB
    ANNALS OF ONCOLOGY, 2002, 13 (01) : 40 - 43
  • [43] SENSITIVITY OF IMMUNOLOGICAL FECAL OCCULT BLOOD TESTING IN COLORECTAL-CANCER, USING TOTAL COLONOSCOPY AS THE CRITERION STANDARD
    MITSUSHIMA, T
    NAGATANI, K
    IKUMA, H
    INOUE, A
    UENO, F
    GASTROENTEROLOGY, 1994, 106 (04) : A416 - A416
  • [44] The Role of Fecal Occult Blood Testing in Screening for Colorectal Cancer
    Allison, James E.
    PRACTICAL GASTROENTEROLOGY, 2007, 31 (06) : 20 - 32
  • [45] Test Performance of Immunologic Fecal Occult Blood Testing and Sigmoidoscopy Compared with Primary Colonoscopy Screening for Colorectal Advanced Adenomas
    Khalid-de Bakker, Carolina A. J.
    Jonkers, Daisy M. A. E.
    Sanduleanu, Silvia
    de Bruine, Adriaan P.
    Meijer, Gerrit A.
    Janssen, Jan B. M. J.
    van Engeland, Manon
    Stockbruegger, Reinhold W.
    Masclee, Ad A. M.
    CANCER PREVENTION RESEARCH, 2011, 4 (10) : 1563 - 1571
  • [46] RANDOMIZED, CONTROLLED TRIAL OF FECAL OCCULT BLOOD SCREENING FOR COLORECTAL-CANCER - RESULTS FOR 1ST 107349-SUBJECTS
    HARDCASTLE, JD
    CHAMBERLAIN, J
    SHEFFIELD, J
    BALFOUR, TW
    ARMITAGE, NC
    THOMAS, WM
    PYE, G
    JAMES, PD
    AMAR, SS
    MOSS, SM
    LANCET, 1989, 1 (8648): : 1160 - 1164
  • [47] Immunochemical Fecal Occult Blood Test for Detection of Advanced Colonic Adenomas and Colorectal Cancer: Comparison with Colonoscopy Results
    Viana Freitas, Bianca Rosa
    Nagasako, Cristiane Kibune
    Pavan, Celia Regina
    Silva Lorena, Sonia Leticia
    Guerrazzi, Fabio
    Rodrigues Coy, Claudio Saddy
    Ayrizono, Maria de Lourdes S.
    Mesquita, Maria Aparecida
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2013, 2013
  • [48] FECAL OCCULT BLOOD TESTING AND COLONOSCOPY IN THE SURVEILLANCE OF SUBJECTS AT HIGH-RISK OF COLORECTAL NEOPLASIA
    ROBINSON, MHE
    KRONBORG, O
    WILLIAMS, CB
    BOSTOCK, K
    ROONEY, PS
    HUNT, LM
    HARDCASTLE, JD
    BRITISH JOURNAL OF SURGERY, 1995, 82 (03) : 318 - 320
  • [49] Where does it FIT? The roles of fecal testing and colonoscopy in colorectal cancer screening
    Hillyer, Grace Clarke
    Neugut, Alfred I.
    CANCER, 2015, 121 (18) : 3186 - 3189
  • [50] A Randomized Controlled Trial Testing Provision of Fecal and Blood Test Options on Participation for Colorectal Cancer Screening
    Symonds, Erin L.
    Hughes, Donna
    Flight, Ingrid
    Woodman, Richard
    Chen, Gang
    Ratcliffe, Julie
    Pedersen, Susanne K.
    Fraser, Robert J. L.
    Young, Graeme P.
    Wilson, Carlene J.
    CANCER PREVENTION RESEARCH, 2019, 12 (09) : 631 - 639